Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety & efficacy of Brisdelle (paroxetine
mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with
menopause.